直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Podcast

SaMD Series: What Should Life Sciences Companies Know?

August 14, 2018

By Eric P. Raciti; Cory C. Bell

Software as a Medical Device – also referred to as SaMD – is one of the fastest growing innovations in the medical device industry. As with any technology that experiences rapid adoption, challenges related to IP protection often follow. In this series, we’re taking a closer look at IP considerations that SaMD developers should be aware of.

In this podcast, Finnegan attorneys Eric Raciti and Cory Bell explore nuances of IP law that life sciences companies should consider when developing an SaMD.

Tags

software as a medical device (SaMD), Podcast Series: Software as a Medical Device (SaMD)

Downloadable Files

  • Raciti_Bell_SaMD_Life Sciences_08-14-18

Related Industries

AI, Electronics, and Information Technology

Electrical and Computer Technology

Life Sciences

Pharmaceutical

Related Offices

Boston, MA

Related Professionals

Eric P. Raciti
Partner
Boston, MA
+1 617 646 1675
Email
Cory C. Bell
Partner
Boston, MA
+1 617 646 1641
Email

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

Articles

Article_D.-Mass-Patent-Litigation-Update-October-2024

D. Mass. Patent Litigation Update: April 2026

June 1, 2026

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

Conference

BIA Start-up Festival

May 21, 2026

London

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Articles

COPPA’s Amended Rule Is Now in Full Effect: What Operators Need to Know

May 15, 2026

Conference

2026 Advanced Chemical & Biotech Patent Institute

May 11-12, 2026

San Francisco

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP